Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

1.

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.

Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.

Neurology. 2013 Oct 22;81(17):1515-22. doi: 10.1212/WNL.0b013e3182a95680. Epub 2013 Sep 25.

PMID:
24068788
[PubMed - indexed for MEDLINE]
2.

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.

PMID:
24160898
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G.

Neuro Oncol. 2012 Sep;14 Suppl 4:iv100-8. doi: 10.1093/neuonc/nos206. Review.

PMID:
23095825
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.

Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T.

Neuro Oncol. 2012 Jan;14(1):109-16. doi: 10.1093/neuonc/nor185. Epub 2011 Oct 27.

PMID:
22039037
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.

Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P.

Mod Pathol. 2013 Jul;26(7):922-9. doi: 10.1038/modpathol.2012.166. Epub 2013 Feb 22.

PMID:
23429602
[PubMed - indexed for MEDLINE]
Free Article
6.

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.

PMID:
20160062
[PubMed - indexed for MEDLINE]
Free Article
7.

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.

J Clin Oncol. 2009 Dec 10;27(35):5874-80. doi: 10.1200/JCO.2009.23.6497. Epub 2009 Nov 9. Erratum in: J Clin Oncol. 2010 Feb 1;28(4):708.

PMID:
19901110
[PubMed - indexed for MEDLINE]
8.

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.

Chamberlain MC.

Neurology. 2014 Jun 10;82(23):2147-8. doi: 10.1212/01.wnl.0000451452.30826.6b. No abstract available.

PMID:
24912510
[PubMed - indexed for MEDLINE]
9.

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.

Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schackert G, Krex D.

J Neurooncol. 2012 Dec;110(3):325-33. doi: 10.1007/s11060-012-0977-2. Epub 2012 Sep 27. Erratum in: J Neurooncol. 2013 Jan;111(1):95. Schrok, E [corrected to Schrock, E].

PMID:
23015095
[PubMed - indexed for MEDLINE]
10.

Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.

Laxton RC, Popov S, Doey L, Jury A, Bhangoo R, Gullan R, Chandler C, Brazil L, Sadler G, Beaney R, Sibtain N, King A, Bodi I, Jones C, Ashkan K, Al-Sarraj S.

Neuro Oncol. 2013 Dec;15(12):1635-43. doi: 10.1093/neuonc/not125. Epub 2013 Oct 24.

PMID:
24158110
[PubMed - indexed for MEDLINE]
11.

Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.

Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J.

Neurol Med Chir (Tokyo). 2007 Aug;47(8):341-9; discussion 350.

PMID:
17721049
[PubMed - indexed for MEDLINE]
Free Article
12.

Molecular profile of oligodendrogliomas in young patients.

Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, Shukla S, Somasundaram K, Mahapatra AK, Kale SS, Sarkar C.

Neuro Oncol. 2011 Oct;13(10):1099-106. doi: 10.1093/neuonc/nor146.

PMID:
21937591
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.

PMID:
22287028
[PubMed - indexed for MEDLINE]
14.

Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.

Ochsenbein AF, Schubert AD, Vassella E, Mariani L.

J Neurooncol. 2011 Jun;103(2):343-51. doi: 10.1007/s11060-010-0395-2. Epub 2010 Sep 21.

PMID:
20857319
[PubMed - indexed for MEDLINE]
15.

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.

Neurology. 2010 Oct 26;75(17):1560-6. doi: 10.1212/WNL.0b013e3181f96282.

PMID:
20975057
[PubMed - indexed for MEDLINE]
16.

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M.

J Clin Oncol. 2009 Dec 1;27(34):5743-50. doi: 10.1200/JCO.2009.23.0805. Epub 2009 Oct 5.

PMID:
19805672
[PubMed - indexed for MEDLINE]
17.

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, Ibdaih A, Brandes AA, Taphoorn MJ, Frenay M, Lacombe D, Gorlia T, Dinjens WN, Kros JM.

J Clin Oncol. 2009 Dec 10;27(35):5881-6. doi: 10.1200/JCO.2009.24.1034. Epub 2009 Nov 9.

PMID:
19901104
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1349-55. doi: 10.3174/ajnr.A2950. Epub 2012 Feb 9.

PMID:
22322613
[PubMed - indexed for MEDLINE]
Free Article
19.

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.

Taal W, Dubbink HJ, Zonnenberg CB, Zonnenberg BA, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Kros JM, Kouwenhoven MC, van Marion R, van Heuvel I, van der Holt B, Bromberg JE, Sillevis Smitt PA, Dinjens WN, van den Bent MJ; Dutch Society for Neuro-Oncology.

Neuro Oncol. 2011 Feb;13(2):235-41. doi: 10.1093/neuonc/noq177. Epub 2010 Dec 21.

PMID:
21177338
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.

Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T.

PLoS One. 2011;6(8):e23332. doi: 10.1371/journal.pone.0023332. Epub 2011 Aug 4.

PMID:
21829728
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk